| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 2.5 |
| Gross profit | 0.0 | 0.4 |
| Profit before tax | -1.1 | -0.7 |
| Net income | -1.1 | -0.7 |
| EPS (diluted, $ a share) | $-0.39 | $-0.40 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -98.1% |
|---|---|
| Gross margin | 9.4% |
10-Q filed with the SEC, NASDAQ: BGLC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
BioNexus Gene Lab Corp: key numbers
- Share price
- $0.6800Close, Nov 20
- Market cap
- $2.34M
- Shares outstanding
- 3.49MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from BioNexus Gene Lab Corp
All →BioNexus Gene Lab Licensing Deal with Ruanyun Edai Technology Inc. Worth $3.5M
BioNexus Gene Lab Corp. entered into an exclusive 10-year licensing agreement with Ruanyun Edai Technology Inc. (RYET) for the CogniAI document-intelligence platform in the Malaysian healthcare sector. The company will issue 410,000 shares to satisfy the $3.5 million license consideration and an additional 150,000 shares in exchange for 500,000 RYET ordinary shares. BioNexus intends to use the platform to target Malaysia's RM1 billion public healthcare digitalization program.
- Value
- $3.5M
- Counterparty
- Ruanyun Edai Technology Inc.
- Term
- 10 years